FCS Real-World Evidence Capabilities Contributing to Breakthroughs In Blood Cancer Treatment Worldwide
Florida Cancer Specialists & Research Institute Real-World Evidence Capabilities Contributing to Breakthroughs In Blood Cancer Treatment Worldwide
Fort Myers, Fla., September 24, 2024 – Clinical research findings utilizing real-world data and conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) will be shared with a pre-eminent global audience focused on advancing the diagnosis and treatment of multiple myeloma, a rare blood cancer and the second most common hematologic malignancy in the U.S. The abstract, “Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma,” will be presented at the International Myeloma Society 21st Annual Meeting in Rio De Janeiro, Brazil.
Co-authors of the abstract are Lucio N. Gordan, MD, FCS president and managing physician, Amanda Warner, MS, BSN, RN, OCN, CAPM, FCS Director of Real-World Evidence, Gustavo Fonseca, MD, FACP, FCS medical oncologist and hematologist, Trevor Heritage, PhD, FCS senior vice president and data officer, and Amy Ming, FCS senior director of informatics. The research was conducted in partnership with Janssen Scientific Affairs, LLC.
Dr. Gordan said, “Although there is no cure for multiple myeloma, we are making steady progress to enhance the quality of life and outcomes for patients with this disease.”
“Our ability to tap real-world data derived from the treatment FCS provides to more than one million patients, combined with industry-leading data science, has a significant positive impact in our understanding of blood cancers and many other diseases.”
Multiple myeloma (MM) affects white plasma in the bone marrow. Cancerous tumors can weaken the body’s immune system, damage bones and lead to end-organ damage. MM is the second most common hematologic malignancy in the U.S. Two thirds of newly-diagnosed patients are age 65 years or older. There is no cure; the median age at death is 75 years.
The International Myeloma Society, a membership organization comprised of basic research scientists, clinical investigators, physicians and other healthcare practitioners, works to promote research, clinical studies (including diagnosis and treatment) and educational opportunities on all aspects of multiple myeloma worldwide.
Abstracts presented at the IMS 2024 Conference will be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal.
